MAK and cancer: The E-value, hydrogen bonds and binding residues of A2K2A17 and A11K3A11 with target proteins: braf kinase domain, CDPK-2, MAK-ERK-1, ILGF-1, PDGF-1, VEGF, NFKB and kit kinase domain involved in cancer pathway along with standard drugs are shown in Table 3.